Next Article in Journal
The Flexibility of Ectopic Lipids
Next Article in Special Issue
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome
Previous Article in Journal
Analysis of Small RNAs in Streptococcus mutans under Acid Stress—A New Insight for Caries Research
Previous Article in Special Issue
Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(9), 1552; doi:10.3390/ijms17091552

Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment

OncoStem Biotherapeutics LLC, 423 W 127th St., New York, NY 10027, USA
Academic Editor: William Chi-shing Cho
Received: 5 August 2016 / Revised: 5 September 2016 / Accepted: 7 September 2016 / Published: 14 September 2016
(This article belongs to the Collection Advances in Molecular Oncology)
View Full-Text   |   Download PDF [1077 KB, uploaded 14 September 2016]   |  

Abstract

It has been declared repeatedly that cancer is a result of molecular genetic abnormalities. However, there has been no working model describing the specific functional consequences of the deranged genomic processes that result in the initiation and propagation of the cancer process during carcinogenesis. We no longer need to question whether or not cancer arises as a result of a molecular genetic defect within the cancer cell. The legitimate questions are: how and why? This article reviews the preeminent data on cancer molecular genetics and subsequently proposes that the sentinel event in cancer initiation is the aberrant production of fused transcription activators with new molecular properties within normal tissue stem cells. This results in the production of vital oncogenes with dysfunctional gene activation transcription properties, which leads to dysfunctional gene regulation, the aberrant activation of transduction pathways, chromosomal breakage, activation of driver oncogenes, reactivation of stem cell transduction pathways and the activation of genes that result in the hallmarks of cancer. Furthermore, a novel holistic molecular genetic model of cancer initiation and progression is presented along with a new paradigm for the approach to personalized targeted cancer therapy, clinical monitoring and cancer diagnosis. View Full-Text
Keywords: oncogenes; oncogene addiction; carcinogenesis; transcription factor; cancer genome; gene fusion; cancer genetics; cancer stem cell; targeted cancer therapy; personalized medicine oncogenes; oncogene addiction; carcinogenesis; transcription factor; cancer genome; gene fusion; cancer genetics; cancer stem cell; targeted cancer therapy; personalized medicine
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Willis, R.E. Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. Int. J. Mol. Sci. 2016, 17, 1552.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top